INOVIO: COMP Issues Positive Opinion For Orphan Drug Designation In The EU For INO-3107

(RTTNews) - INOVIO (INO) announced that the European Committee for Orphan Medicinal Products has provided a positive opinion on the company's application for orphan drug designation in the European Union for INO-3107. The European Commission will provide a final decision on the application within 30 days.

INO-3107 is the company's product candidate that may contribute to the treatment of Recurrent Respiratory Papillomatosis.

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases.

For More Such Health News, visit rttnews.com.